Cargando…
Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1
BACKGROUND: Activated phosphoinositide3-kinase (PI3K) δ syndrome 1 (APDS1) is a novel inborn errors of immunity (IEIs) caused by heterozygous gain of function mutations in PI3Kδ catalytic p110δ (PIK3CD). APDS1 has a spectrum of clinical manifestations. Recurrent respiratory infections, lymphoprolife...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518115/ https://www.ncbi.nlm.nih.gov/pubmed/37742016 http://dx.doi.org/10.1186/s13223-023-00840-0 |
_version_ | 1785109443193602048 |
---|---|
author | Jiang, Lu Hu, Xiaohan Lin, Qiang Chen, Ruyue Shen, Yunyan Zhu, Yun Xu, Qinying Li, Xiaozhong |
author_facet | Jiang, Lu Hu, Xiaohan Lin, Qiang Chen, Ruyue Shen, Yunyan Zhu, Yun Xu, Qinying Li, Xiaozhong |
author_sort | Jiang, Lu |
collection | PubMed |
description | BACKGROUND: Activated phosphoinositide3-kinase (PI3K) δ syndrome 1 (APDS1) is a novel inborn errors of immunity (IEIs) caused by heterozygous gain of function mutations in PI3Kδ catalytic p110δ (PIK3CD). APDS1 has a spectrum of clinical manifestations. Recurrent respiratory infections, lymphoproliferation, hepatosplenomegaly, hyper-IgM syndrome and autoimmunity are the common symptoms of this disease. CASE PRESENTATION: Patient 1 presented with recurrent respiratory infections, hepatosplenomegaly and hyper-IgM syndrome. Patient 2 developed early onset systemic lupus erythematosus (SLE)-like disease with resistant thrombocytopenia. c.3061 G > A and c.2314G > A variants in the PIK3CD gene were detected by whole exome sequencing in two patients respectively. c.2314G > A variant in PIK3CD gene of patient 2 is a newly report. After genetic diagnosis, two patients received sirolimus treatment and sirolimus alleviated clinical manifestations, including hepatosplenomegaly in patient 1 and thrombocytopenia in patient 2. CONCLUSION: Genetics diagnosis should be considered in patients with complicated clinical manifestations with no or insufficient response to the conventional therapies. If whole exome sequencing suggests a variant in PIK3CD gene, sirolimus may relieve hepatosplenomegaly and resistant thrombocytopenia. This is the first report of c.2314G > A variant in PIK3CD gene. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13223-023-00840-0. |
format | Online Article Text |
id | pubmed-10518115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105181152023-09-25 Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1 Jiang, Lu Hu, Xiaohan Lin, Qiang Chen, Ruyue Shen, Yunyan Zhu, Yun Xu, Qinying Li, Xiaozhong Allergy Asthma Clin Immunol Case Report BACKGROUND: Activated phosphoinositide3-kinase (PI3K) δ syndrome 1 (APDS1) is a novel inborn errors of immunity (IEIs) caused by heterozygous gain of function mutations in PI3Kδ catalytic p110δ (PIK3CD). APDS1 has a spectrum of clinical manifestations. Recurrent respiratory infections, lymphoproliferation, hepatosplenomegaly, hyper-IgM syndrome and autoimmunity are the common symptoms of this disease. CASE PRESENTATION: Patient 1 presented with recurrent respiratory infections, hepatosplenomegaly and hyper-IgM syndrome. Patient 2 developed early onset systemic lupus erythematosus (SLE)-like disease with resistant thrombocytopenia. c.3061 G > A and c.2314G > A variants in the PIK3CD gene were detected by whole exome sequencing in two patients respectively. c.2314G > A variant in PIK3CD gene of patient 2 is a newly report. After genetic diagnosis, two patients received sirolimus treatment and sirolimus alleviated clinical manifestations, including hepatosplenomegaly in patient 1 and thrombocytopenia in patient 2. CONCLUSION: Genetics diagnosis should be considered in patients with complicated clinical manifestations with no or insufficient response to the conventional therapies. If whole exome sequencing suggests a variant in PIK3CD gene, sirolimus may relieve hepatosplenomegaly and resistant thrombocytopenia. This is the first report of c.2314G > A variant in PIK3CD gene. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13223-023-00840-0. BioMed Central 2023-09-23 /pmc/articles/PMC10518115/ /pubmed/37742016 http://dx.doi.org/10.1186/s13223-023-00840-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Case Report Jiang, Lu Hu, Xiaohan Lin, Qiang Chen, Ruyue Shen, Yunyan Zhu, Yun Xu, Qinying Li, Xiaozhong Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1 |
title | Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1 |
title_full | Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1 |
title_fullStr | Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1 |
title_full_unstemmed | Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1 |
title_short | Two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1 |
title_sort | two cases of successful sirolimus treatment for patients with activated phosphoinositide 3-kinase δ syndrome 1 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518115/ https://www.ncbi.nlm.nih.gov/pubmed/37742016 http://dx.doi.org/10.1186/s13223-023-00840-0 |
work_keys_str_mv | AT jianglu twocasesofsuccessfulsirolimustreatmentforpatientswithactivatedphosphoinositide3kinasedsyndrome1 AT huxiaohan twocasesofsuccessfulsirolimustreatmentforpatientswithactivatedphosphoinositide3kinasedsyndrome1 AT linqiang twocasesofsuccessfulsirolimustreatmentforpatientswithactivatedphosphoinositide3kinasedsyndrome1 AT chenruyue twocasesofsuccessfulsirolimustreatmentforpatientswithactivatedphosphoinositide3kinasedsyndrome1 AT shenyunyan twocasesofsuccessfulsirolimustreatmentforpatientswithactivatedphosphoinositide3kinasedsyndrome1 AT zhuyun twocasesofsuccessfulsirolimustreatmentforpatientswithactivatedphosphoinositide3kinasedsyndrome1 AT xuqinying twocasesofsuccessfulsirolimustreatmentforpatientswithactivatedphosphoinositide3kinasedsyndrome1 AT lixiaozhong twocasesofsuccessfulsirolimustreatmentforpatientswithactivatedphosphoinositide3kinasedsyndrome1 |